Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

U.S. stocks traded mostly higher toward the end of trading, with the S&P 500 gaining around 0.5% on Tuesday. The Dow traded ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

The drug, called AL002, is designed to activate a group of surveilling neuronal immune cells called microglia. It was among ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...